Terms: = Brain cancer AND BCORL1, ENSG00000085185, 63035, FLJ11362, RP3-510O21_1, B930011H20Rik
60214 results:
1. Maternal and Perinatal Factors Associated With Childhood brain Tumors: A Case-Control Study in Vietnam.
Pham HN; Goldberg RJ; Pham LQ; Nguyen HL; Pham DA; Mai LTT; Phung TL; Hung DQ; Dong HV; Duong HD
Cancer Control; 2024; 31():10732748241258602. PubMed ID: 38783766
[TBL] [Abstract] [Full Text] [Related]
2. Epidemiology of primary brain tumor among adolescents and adults in Palestine: a retrospective study from 2018 to 2023.
Abuawad M; Daqour A; Alkaiyat A; Rjoub A; Zahra WA; Issa N; Dumaidi Y; Nasser S
BMC Neurol; 2024 May; 24(1):168. PubMed ID: 38783212
[TBL] [Abstract] [Full Text] [Related]
3. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
Li X; Wu D; Tang J; Wu Y
J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
[TBL] [Abstract] [Full Text] [Related]
4. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
[TBL] [Abstract] [Full Text] [Related]
5. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.
Zhao J; Cui X; Zhan Q; Zhang K; Su D; Yang S; Hong B; Wang Q; Ju J; Cheng C; Li C; Wan C; Wang Y; Zhou J; Kang C
Theranostics; 2024; 14(7):2835-2855. PubMed ID: 38773970
[No Abstract] [Full Text] [Related]
6. High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial).
Zegers CML; Swinnen A; Roumen C; Hoffmann AL; Troost EGC; van Asch CJJ; Brandts L; Compter I; Dieleman EMT; Dijkstra JB; Granzier M; Hendriks M; Hofman P; Houben RMA; Ramaekers B; Ronner HE; Rouhl RPW; van der Salm S; Santegoeds RGC; Verhoeff JJ; Wagner GL; Zwemmer J; Schijns O; Colon AJ; Eekers DBP
Trials; 2024 May; 25(1):334. PubMed ID: 38773643
[TBL] [Abstract] [Full Text] [Related]
7. MR-based radiomics predictive modelling of EGFR mutation and HER2 overexpression in metastatic brain adenocarcinoma: a two-centre study.
Li Y; Jin Y; Wang Y; Liu W; Jia W; Wang J
Cancer Imaging; 2024 May; 24(1):65. PubMed ID: 38773634
[TBL] [Abstract] [Full Text] [Related]
8. Deformable registration of magnetic resonance images using unsupervised deep learning in neuro-/radiation oncology.
Osman AFI; Al-Mugren KS; Tamam NM; Shahine B
Radiat Oncol; 2024 May; 19(1):61. PubMed ID: 38773620
[TBL] [Abstract] [Full Text] [Related]
9. Clinical presentation and surgical outcomes of very large and giant pituitary adenomas: 80 cases in a cohort study of 306 patients with pituitary adenomas.
Pascual-Corrales E; Acitores Cancela A; Baonza G; Madrid Egusquiza I; Rodríguez Berrocal V; Araujo-Castro M
Acta Neurochir (Wien); 2024 May; 166(1):225. PubMed ID: 38772927
[TBL] [Abstract] [Full Text] [Related]
10. Anchorage Dependence and cancer Metastasis.
Lee DK; Oh J; Park HW; Gee HY
J Korean Med Sci; 2024 May; 39(19):e156. PubMed ID: 38769921
[TBL] [Abstract] [Full Text] [Related]
11. Survival Predictive Nomograms for Non-Surgical brain Metastases Patients From Non-Small Cell Lung cancer Receiving Radiotherapy: A Population-Based Study.
Li P; Luo J; Zheng Z; Meng L; Zhang A; Cao W; Gong X
Cancer Control; 2024; 31():10732748241255212. PubMed ID: 38769789
[TBL] [Abstract] [Full Text] [Related]
12. Identification and characterization of critical values in therapeutic drug monitoring: a retrospective analysis.
Xiao Y; Xu L; Qian Y; Xu Y
Sci Rep; 2024 May; 14(1):11520. PubMed ID: 38769456
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of two region-of-interest placement methods for histogram analysis of apparent diffusion coefficient maps for glioma grading.
Hieu ND; Hung ND; Hung ND; Hien MM; Anh DV; Dung LT
Clin Ter; 2024; 175(3):128-136. PubMed ID: 38767069
[TBL] [Abstract] [Full Text] [Related]
14. Fertility preservation in female cancer patients in Brazil: perceptions and attitudes of infertility specialists.
Ranniger RL; Lamaita RM; D'Abreu BF; Tolentino MR; Cândido EB; Andrade WP; Nogueira-Rodrigues A; Silva-Filho AL
Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 38765513
[TBL] [Abstract] [Full Text] [Related]
15. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
Ho WM; Chen CY; Chiang TW; Chuang TJ
Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
[TBL] [Abstract] [Full Text] [Related]
16. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
GBD 2021 Risk Factors Collaborators
Lancet; 2024 May; 403(10440):2162-2203. PubMed ID: 38762324
[TBL] [Abstract] [Full Text] [Related]
17. IDH1 mutation produces R-2-hydroxyglutarate (R-2HG) and induces mir-182-5p expression to regulate cell cycle and tumor formation in glioma.
Zhao H; Meng L; Du P; Liao X; Mo X; Gong M; Chen J; Liao Y
Biol Res; 2024 May; 57(1):30. PubMed ID: 38760850
[TBL] [Abstract] [Full Text] [Related]
18. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
[TBL] [Abstract] [Full Text] [Related]
19. Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.
Aung TM; Ngamjarus C; Proungvitaya T; Saengboonmee C; Proungvitaya S
PLoS One; 2024; 19(5):e0303337. PubMed ID: 38758750
[TBL] [Abstract] [Full Text] [Related]
20. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract] [Full Text] [Related]
[Next]
